Sanofi-Aventis and Novalar file OraVerse in certain EU countries
This article was originally published in Scrip
Sanofi-Aventis and Novalar Pharmaceuticals have filed OraVerse (phentolamine mesylate) for the reversal of local anaesthesia for the acceleration for normal sensation and function following routine dental procedures in the UK, Germany, Italy, France and Spain.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.